ArticleClinical cancer research : an official journal of the American Association for Cancer Research2025

Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors.

Apostolia M Tsimberidou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.